Current Status of Tissue Engineered Vascular Graft in Pediatric Cardiac Surgery
-
1
Nationwide Children's Hospital, Cardiothoracic Surgery, United States
In 2001, we developed the first tissue engineered vascular graft (TEVG) for use in congenital heart surgery and confirmed its significant potential via an initial clinical trial. The rational design of improved, second-generation TEVGs will be predicated on our understanding of the cellular and molecular mechanisms underlying the formation of TEVG stenosis.
Tissue engineering provides a theoretical method for creating an improved vascular conduit. The feasibility of tissue engineering large caliber, autologous vascular conduits for use as venous interposition grafts for congenital heart surgery has been demonstrated in both large animal and in a human clinical trial. Early results suggest that the use of TEVAs is both safe and efficacious. The carefully designed clinical trial under the supervision of the FDA is now underway in the United States. The development of a readily available vascular graft constructed from autologous tissue that also has growth potential has dramatic implications for the field of congenital heart surgery.
References:
[1] T. Shinoka, et al, New Eng J Med. 2001, 344:532-533.
[2] T. Shinoka, et al, J. Thorac. Cardiovasc. Surg. 2005, 129, 1330
[3] N. Hibino, et al, The FASEB Journal, . 2011, 25: 4253-63
[4] Y. Naito Y, et al, Cells, Tissue and Organs. 2012, 195: 60-72
[5] Y. Naito, et al, Tissue Engineering Part A 2014, 20 (1 and 2): 346-55
Keywords:
Regenerative Medicine,
Tissue Engineering,
blood vessel,
Biodegradable material
Conference:
10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016.
Presentation Type:
Clinical Session: From Clinic to Bench
Topic:
Biomaterials for therapeutic delivery
Citation:
Shinoka
T
(2016). Current Status of Tissue Engineered Vascular Graft in Pediatric Cardiac Surgery.
Front. Bioeng. Biotechnol.
Conference Abstract:
10th World Biomaterials Congress.
doi: 10.3389/conf.FBIOE.2016.01.00201
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
28 Mar 2016;
Published Online:
30 Mar 2016.